Bristol-Myers Squibb hepatitis C drug EU go ahead

Bristol-Myers Squibb has announced that the European Commission has approved Daklinza for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of chronic hepatitis C virus infection in adults.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Hepatic disorders bristol-myers squibb Daklinka european commission hepatitis c virus Latest News Source Type: news